Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002077 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
NCT03002077 is a Phase 3 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 617 participants.
The verdict
NCT03002077, a Phase 3 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
Interventions
- DRUG Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002077
The ClinicalTrials.gov registry entry for NCT03002077 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapastinel is the first listed.
NCT03002077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002077 about?
NCT03002077 is a clinical study titled "Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder". This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
What is the current status of trial NCT03002077?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2017-02-03. Estimated completion is 2018-12-06.
What interventions are being tested in trial NCT03002077?
The interventions under investigation include: Rapastinel (DRUG).
Who is sponsoring clinical trial NCT03002077?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.